Video

Dr. Tripathy on Decision-Making for Sequencing Therapies for HER2-Positive MBC

Debu Tripathy, MD, discusses a decision-making framework for sequencing therapies for HER2-positive metastatic breast cancer.

Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses a decision-making framework for sequencing therapies for HER2-positive metastatic breast cancer.

While there are some broad frameworks in place for decision-making, Tripathy says, many patients do not fit easily into those frameworks. In the first-line, patients who have not been treated with trastuzumab (or were treated with trastuzumab over one year ago) should receive a combination of trastuzumab, pertuzumab, and docetaxel or another taxane. The question then remains as to how this group should be treated next, Tripathy says.

It is known that T-DM1 is superior to capecitabine and lapatinib, but again, questions remain regarding what should be done when a patient progresses in a short period of time. Tripathy says oncologists can treat based on phase II results, but there is no way to definitively know what is best for a given situation.

Related Videos
Sheldon M. Feldman, MD
David Rimm, MD, PhD
In this episode of OncChats: Empowering Community Cancer Care, Dr. Rai emphasizes the importance of community outreach and support for patients with cancer, highlighting the need for holistic care that addresses both physiological and psychological aspects of treatment while reinforcing the value of strong relationships between primary care physicians and specialists.
In this episode of OncChats: Empowering Community Cancer Care, Dr. Woodworth sheds light on the “Road to Recovery” survivorship program at Henry Mayo, which supports cancer survivors by providing them with fitness, education, and mental health resources, and underscores the importance of mentorship programs for community providers to ensure equitable cancer care.
In this episode of OncChats: Empowering Community Cancer Care, Drs Woodworth and Rai, discuss their collaborative approach to cancer screening, emphasizing the importance of community efforts and individual assessments in integrating genetic testing and screenings into routine practice.
In this episode of OncChats: Empowering Community Cancer Care, experts discuss the significance of community-based cancer care, emphasizing that most cancers are diagnosed locally and highlighting the importance of collaboration between primary care physicians and specialists to provide optimal education and treatment.
Sunil Adige, MD
Nancy U. Lin, MD, associate chief, Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers, director, Metastatic Breast Cancer Program, director, Program for Patients with Breast Cancer Brain Metastases, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School
Oleg Gluz, MD